To: Dr Julian Elliott Executive Director National Covid Clinical Evidence […]

The Health Practitioner Regulation Agency declined to proceed against a doctor who prescribed ivermectin for the China virus, a decision endorsed by Health Minister Greg Hunt. So where does the Pharmaceutical Society get the chutzpah to inform members they should overrule prescribing physicians and "decline to supply ivermectin for the treatment or prevention of COVID-19"?

In a letter to the Executive Director of the National COVID Clinical Evidence Taskforce, backed up by an outside consultancy's damning appraisal of the panel's logic, Dr Phillip Altman demands straight answers to the key question: Why aren't COVID-infected individuals receiving the benefits of ivermentin's cheap, off-patent and effective treatment?

Among the many riddles of the virus, starting with the circumstances of its creation in Wuhan, we can only wonder at the especially baffling TGA edict banning ivermectin and hydroxychloroquine. A pharmacologist involved in drug development, clinical trials and drug registration for 40 years addresses those mysteries and much, much more